Just like a puzzle with interlocking pieces, new research has unveiled a surprising connection between COVID-19 and Alzheimer’s disease. Scientists have discovered that these two seemingly unrelated conditions share a genetic architecture, meaning they have underlying genetic similarities. While the focus during the pandemic has been on reducing COVID-19 morbidity and mortality, it’s now crucial to investigate the long-term effects of the virus, including cognitive impairment in those with ‘long COVID.’ Recent studies have shown a potential link between COVID-19 and Alzheimer’s, which is one of the leading causes of cognitive decline associated with aging.
By analyzing genome-wide association studies, researchers identified common susceptibility genes that contribute to both diseases. Additionally, they highlighted specific genetic markers known as SNPs that may be indicative of cognitive impairment in individuals with long COVID. Understanding this shared genetic background opens up new avenues for exploring potential treatment strategies and preventative measures for both conditions.
To dive deeper into the fascinating study linking COVID-19 and Alzheimer’s, check out the research article below!
The severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) and the сoronavirus disease 2019 (COVID-19) have become a global health threat. At the height of the pandemic, major efforts were focused on reducing COVID-19-associated morbidity and mortality. Now is the time to study the long-term effects of the pandemic, particularly cognitive impairment associated with long COVID. In recent years much attention has been paid to the possible relationship between COVID-19 and Alzheimer’s disease, which is considered a main cause of age-related cognitive impairment. Genetic predisposition was shown for both COVID-19 and Alzheimer’s disease. However, the analysis of the similarity of the genetic architecture of these diseases is usually limited to indicating a positive genetic correlation between them. In this review, we have described intrinsic linkages between COVID-19 and Alzheimer’s disease, pointed out shared susceptibility genes that were previously identified in genome-wide association studies of both COVID-19 and Alzheimer’s disease, and highlighted a panel of SNPs that includes candidate genetic risk markers of the long COVID-associated cognitive impairment.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.